BIOD-250 Ultra-rapid-acting insulin analogues (Albiero Pharma)

N/A

Report date: 2022/11/25 17:02:00

Base Information

Drug NameBIOD-250 Ultra-rapid-acting insulin analogues (Albiero Pharma)
Drug Alias NameBIOD-250
ClassificationBiologics
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiodel Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiodel Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A